High-strength testosterone undecanoate compositions
The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone C max to serum testosterone C ave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration C ave range for a male subject is provided.
1. A method for replacement therapy in a male having a condition associated with a deficiency or absence of endogenous testosterone said method comprising:
(a) orally administering to a male identified as having a morning serum testosterone level below normal, a daily dosing regimen of a pharmaceutical composition in one capsule in the morning and in one capsule in the evening, with food, said pharmaceutical composition comprising about 18 weight % (wt %) to about 25 wt % testosterone undecanoate and a carrier comprising oleic acid, polyoxyl 40 hydrogenated castor oil, and borage seed oil, that provides about 450 mg to 480 mg testosterone undecanoate to said male per day; and
(b) orally administering to the male, following a determination of the male's serum testosterone level at about 6 hours after single dose of the pharmaceutical composition at steady state during the daily dosing regimen, a daily dosing regimen of a pharmaceutical composition once in the morning and once in the evening, with food, comprising about 18 wt % to about 25 wt % testosterone undecanoate and a carrier comprising oleic acid, polyoxyl 40 hydrogenated castor oil, and borage seed oil, that provides within plus/minus 40% of about 450 mg to 480 mg of testosterone undecanoate to said male per day to provide a serum testosterone C ave in said male in the range of from about 300 to 1100 ng/dL and a C max of less than 2500 ng/dL.
2. The method of claim 1 , wherein the C max is less than 1500 ng/dL.
3. The method of claim 2 , wherein said pharmaceutical composition comprises about 52 wt % oleic acid.
4. The method of claim 3 , wherein said pharmaceutical composition comprises about 20 wt % testosterone undecanoate.
5. The method of claim 4 , wherein said pharmaceutical composition comprises about 16 wt % polyoxyl 40 hydrogenated castor oil.
6. The method of claim 1 , wherein said daily dosing regimen of (a) provides about 480 mg per day of testosterone undecanoate.
7. The method of claim 1 , wherein said daily dosing regimen of (b) provides within plus 40% of about 450 mg to 480 mg testosterone undecanoate and said pharmaceutical composition is provided in two capsules in the morning and in two capsules in the evening.
8. The method of claim 1 , wherein said daily dosing regimen of (b) provides within minus 40% of about 450 mg to 480 mg testosterone undecanoate per day.
9. The method of claim 1 , wherein said daily dosing regimen of (b) provides within plus 33% of about 450 mg to 480 mg testosterone undecanoate per day and said pharmaceutical composition is provided in two capsules in the morning and in two capsules in the evening.
10. The method of claim 5 , wherein said daily dosing regimen of (a) provides about 480 mg per day of testosterone undecanoate.
11. The method of claim 5 , wherein said daily dosing regimen of (b) provides within plus 40% of about 450 mg to 480 mg testosterone undecanoate and said pharmaceutical composition is provided in two capsules in the morning and in two capsules in the evening.
12. The method of claim 5 , wherein said daily dosing regimen of (b) provides within minus 40% of about 450 mg to 480 mg testosterone undecanoate per day.
13. The method of claim 5 , wherein said daily dosing regimen of (b) provides within plus 33% of about 450 mg to 480 mg testosterone undecanoate per day and said pharmaceutical composition is provided in two capsules in the morning and in two capsules in the evening.
14. The method of claim 1 , further comprising orally administering to the male, following a determination of the male's serum testosterone level at about 6 hours after single dose of the pharmaceutical composition at steady state during the daily dosing regimen of step (b), a daily dosing regimen of a pharmaceutical composition comprising about 18 wt % to about 25 wt % testosterone undecanoate and a carrier comprising oleic acid, polyoxyl 40 hydrogenated castor oil, and borage seed oil, that provides within plus/minus 40% of the testosterone undecanoate administered to said male per day in step (b) to provide a serum testosterone C ave in said male in the range of from about 300-1100 ng/dL.
15. The method of claim 5 , further comprising orally administering to the male, following a determination of the male's serum testosterone level at about 6 hours after single dose of the pharmaceutical composition at steady state during the daily dosing regimen of step (b), a daily dosing regimen of a pharmaceutical composition comprising about 18 wt % to about 25 wt % testosterone undecanoate and a carrier comprising oleic acid, polyoxyl 40 hydrogenated castor oil, and borage seed oil, that provides within plus/minus 40% of the testosterone undecanoate administered to said male per day in step (b) to provide a serum testosterone C ave in said male in the range of from about 300-1100 ng/dL.
16. The method of claim 6 , further comprising orally administering to the male, following a determination of the male's serum testosterone level at about 6 hours after single dose of the pharmaceutical composition at steady state during the daily dosing regimen of step (b), a daily dosing regimen of a pharmaceutical composition comprising about 18 wt % to about 25 wt % testosterone undecanoate and a carrier comprising oleic acid, polyoxyl 40 hydrogenated castor oil, and borage seed oil, that provides within plus/minus 40% of the testosterone undecanoate administered to said male per day in step (b) to provide a serum testosterone C ave in said male in the range of from about 300-1100 ng/dL.
17. The method of claim 7 , further comprising orally administering to the male, following a determination of the male's serum testosterone level at about 6 hours after single dose of the pharmaceutical composition at steady state during the daily dosing regimen of step (b), a daily dosing regimen of a pharmaceutical composition comprising about 18 wt % to about 25 wt % testosterone undecanoate and a carrier comprising oleic acid, polyoxyl 40 hydrogenated castor oil, and borage seed oil, that provides within plus/minus 40% of the testosterone undecanoate administered to said male per day in step (b) to provide a serum testosterone C ave in said male in the range of from about 300-1100 ng/dL.
18. The method of claim 1 , wherein said pharmaceutical composition provides upon single dose administration a ratio of serum testosterone C max to C ave of about 2.7 or less.
19. The method of claim 4 , wherein said pharmaceutical composition provides upon single dose administration a dose-normalized serum testosterone C ave of about 1.9×10-6 dL-1 or higher.
20. The method of claim 5 , wherein said pharmaceutical composition provides upon single dose administration a ratio of serum testosterone C max to C ave of about 2.7 or less.
21. The method of claim 6 , wherein said pharmaceutical composition provides upon single dose administration a dose-normalized serum testosterone C ave of about 1.9×10-6 dL-1 or higher.
22. The method of claim 7 , wherein said pharmaceutical composition provides upon single dose administration a ratio of serum testosterone C max to C ave of about 2.7 or less.
23. The method of claim 8 , wherein said pharmaceutical composition provides upon single dose administration a dose-normalized serum testosterone C ave of about 1.9×10-6 dL-1 or higher.
24. The method of claim 9 , wherein said pharmaceutical composition provides upon single dose administration a ratio of serum testosterone C max to C ave of about 2.7 or less.
25. The method of claim 10 , wherein said pharmaceutical composition provides upon single dose administration a dose-normalized serum testosterone C ave of about 1.9×10-6 dL-1 or higher.
26. The method of claim 11 , wherein said pharmaceutical composition provides upon single dose administration a ratio of serum testosterone C max to C ave of about 2.7 or less.
27. The method of claim 12 , wherein said pharmaceutical composition provides upon single dose administration a dose-normalized serum testosterone C ave of about 1.9×10-6 dL-1 or higher.
28. A method for replacement therapy in a male having a condition associated with a deficiency or absence of endogenous testosterone said method comprising:
(a) orally administering to a male identified as having a morning serum testosterone level of less than normal a daily dosing regimen of a pharmaceutical composition in one capsule the morning and one capsule in the evening, with food, said pharmaceutical composition comprising about 18 weight % (wt %) to about 25 wt % testosterone undecanoate and a carrier comprising about 52 wt % oleic acid, about 16 wt % polyoxyl 40 hydrogenated castor oil, and borage seed oil, that provides about 450 mg to 480 mg testosterone undecanoate to said male per day; and
(b) orally administering to the male, following a determination of the male's serum testosterone level at about 6 hours after single dose of the pharmaceutical composition during the daily dosing regimen, a daily dosing regimen of a pharmaceutical composition in two capsules in the morning and two capsules in the evening, with food, said pharmaceutical comprising about 18 wt % to about 25 wt % testosterone undecanoate and a carrier comprising oleic acid, polyoxyl 40 hydrogenated castor oil, and borage seed oil, that provides plus 33% of about 450 mg to 480 mg of testosterone undecanoate to said male per day to provide a serum testosterone C ave in said male in the range of from about 300-1100 ng/dL.
29. The method of claim 28 , wherein said pharmaceutical composition provides upon single dose administration a ratio of serum testosterone C max to C ave of about 2.7 or less.
30. The method of claim 29 , wherein said pharmaceutical composition provides upon single dose administration a dose-normalized serum testosterone C ave of about 1.9×10-6 dL-1 or higher.